Influence of ryanodyne receptor 1 mutations on pulmonary arterial pressure and ventilation during isocapnic hypoxia

Published: 23-05-2011 Last updated: 27-04-2024

W want to investigate the influence of a mutaion in the MH allel on the HPV and the normal reaction of MH patients to hypoxia

Ethical review Approved WMO **Status** Will not start

Health condition type Vascular hypertensive disorders

Study type Interventional

Summary

ID

NL-OMON36376

Source

ToetsingOnline

Brief title

Ryan op pad

Condition

Vascular hypertensive disorders

Synonym

pulmonary hypertension

Research involving

Human

Sponsors and support

Primary sponsor: Leids Universitair Medisch Centrum

Source(s) of monetary or material Support: Ministerie van OC&W

1 - Influence of ryanodyne receptor 1 mutations on pulmonary arterial pressure and v ... 29-06-2025

Intervention

Keyword: HPV, HVR, hypoxia, ryanodine receptor

Outcome measures

Primary outcome

HPV

Secondary outcome

cardiac parameters

hypoxic ventilatory response

Study description

Background summary

During hypoxia, a phenomenon called hypoxic pulmonary vasoconstriction, occurs. This reaction protects the body by lowering bloodflow to less ventilated parts of the long. This protecting mechanism can also harm the patient. This is the case with COPD and the development of pulmonary hypertension. The ryanodine receptor plays an important role in HPV. MH patients have a mutation in the ryanodine receptor gen and studies in mice show a different reaction to hypoxia.

Study objective

W want to investigate the influence of a mutaion in the MH allel on the HPV and the normal reaction of MH patients to hypoxia

Study design

case controlled intervention study

Intervention

hypoxia

Study burden and risks

headache during hypoxia somethimes occurs, which is treated with paracetamol a bruise may occur on the spot of the iv

Contacts

Public

Leids Universitair Medisch Centrum

albinusdreef 2 2333 ZA, Leiden NL

Scientific

Leids Universitair Medisch Centrum

albinusdreef 2 2333 ZA, Leiden NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Healthy Malignant Hyperthermia patients with a phenotypic high susceptibility and a proven causative mutation.

The major inclusion criteria are that the subject has echo evidence of tricuspid regurgitation during systole, which is not clinically relevant but in fact can be demonstrated in most normal individuals.

Exclusion criteria

- Obesity (BMI > 30)
- Presence of medical disease: heart-, lung-, liver-, kidney- and lung disease; diabetes
- Presence of psychiatric disease
- History of chronic alcohol or drug use
- Possibility of pregnancy
- Lactation

Study design

Design

Study type: Interventional

Intervention model: Other

Allocation: Non-randomized controlled trial

Masking: Open (masking not used)

Control: Active

Primary purpose: Basic science

Recruitment

NL

Recruitment status: Will not start

Enrollment: 24

Type: Anticipated

Ethics review

Approved WMO

Date: 23-05-2011

Application type: First submission

Review commission: METC Leids Universitair Medisch Centrum (Leiden)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL35083.058.11